A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Completed · Phase 2 · Has a placebo group

Conditions studied: Heart Failure

In brief

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.

Key facts

Study ID
NCT03098979
Run by
Bayer
People needed
305
Starts
2017-05-10
Expected to finish
2018-06-20
Last updated by the study team
2019-07-23

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.